BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder

  • BridgeBio Pharma Inc BBIO and affiliate company Phoenix Tissue Repair announced data from the Phase 2 trial of PTR-01 in recessive dystrophic epidermolysis bullosa (RDEB). 
  • PTR-01 is an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy.
  • RDEB is one of the most severe forms of epidermolysis bullosa, characterized by severe and painful skin blistering.
  • The data exhibited that PTR-01 was well tolerated when given once per week for 4 weeks and then every other week for 14 weeks.
  • In addition, treatment with PTR-01 led to rapid, consistent, and durable wound healing, as observed in the reduction of wound surface area and clinician-reported assessments. 
  • Specifically, over 80% of target wounds (21/26) demonstrated a 50% or greater reduction in wound surface area at the end of treatment (day 120) compared to baseline. 
  • This response was observed in a breadth of wound types. 
  • Notably, all patients who completed the study (N=5) reported a decrease in pain over treatment with PTR-01. 
  • There was a 36% mean reduction in total pain from the end of the study compared to baseline.
  • Phoenix Tissue Repair has initiated a Phase 2 extension study.
  • Price Action: BBIO shares are down 1.76% at $7.26 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!